

CURRICULUM VITAE
Claire Holmquist, PA-C

Practice Address: Darst Dermatology, PC
11301 Golf Links Drive North, Suite 203
Charlotte, NC 28277
cholmquist@darstderm.com

Site Affiliation: DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

| | |
|-----------|---|
| 2016-2018 | Masters in Physician Assistant Studies Wingate University Physician Assistant Program Wingate, North Carolina |
| 2012-2016 | Bachelor of Arts in Biology Nebraska Wesleyan University Lincoln, Nebraska |

Healthcare Experience:

| | |
|--------------|--|
| 2019-Present | Darst Dermatology, PC Physician Assistant – Certified |
| 2015 | Celerion Clinical Research Clinical Conduct Associate |

Certifications:

| | |
|--------------|--|
| 2017-Present | Advanced Cardiac Life Support (ACLS) |
| 2017-Present | Basic Life Support (BLS) |
| 2018-Present | National Commission on Certification of Physician Assistants |

Professional Memberships:

| | |
|--------------|---|
| 2016-2017 | Wingate University Physician Assistant Student Society, Class Historian |
| 2016-Present | American Academy of Physician Assistants |
| 2016-Present | North Carolina Academy of Physician Assistants |
| 2018-Present | Metrolina Association of Physician Assistants |

Clinical Research:

Sub-Investigator – Vanda Pharmaceuticals Inc- A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3101) (2019)

Sub-Investigator – Chemocentryx Protocol - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

Sub-Investigator – Skintech - A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

CURRICULUM VITAE
Claire Holmquist, PA-C

Sub-Investigator – Trevi Therapeutics: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) 2019


Sub-Investigator – Abbvie: A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis. 2019


Sub-Investigator – Vanda Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3102). 2019

Sub-Investigator – Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Sub-Investigator – Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.


Signature


Date